ロード中...
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling are established contributors to malignant glioma (MG) biology. We, therefore, evaluated bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination with the EGFR tyrosine kinase inhibitor erlot...
保存先:
| 主要な著者: | , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2010
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3018944/ https://ncbi.nlm.nih.gov/pubmed/20716591 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noq099 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|